Browse > Article
http://dx.doi.org/10.1016/j.jgr.2017.09.005

Biosynthesis of rare 20(R)-protopanaxadiol/protopanaxatriol type ginsenosides through Escherichia coli engineered with uridine diphosphate glycosyltransferase genes  

Yu, Lu (School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University)
Chen, Yuan (Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, MOE Key Laboratory for Standardization of Chinese Medicines, SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine)
Shi, Jie (Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, MOE Key Laboratory for Standardization of Chinese Medicines, SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine)
Wang, Rufeng (Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, MOE Key Laboratory for Standardization of Chinese Medicines, SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine)
Yang, Yingbo (Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, MOE Key Laboratory for Standardization of Chinese Medicines, SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine)
Yang, Li (Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, MOE Key Laboratory for Standardization of Chinese Medicines, SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine)
Zhao, Shujuan (Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, MOE Key Laboratory for Standardization of Chinese Medicines, SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Shanghai University of Traditional Chinese Medicine)
Wang, Zhengtao (School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University)
Publication Information
Journal of Ginseng Research / v.43, no.1, 2019 , pp. 116-124 More about this Journal
Abstract
Background: Ginsenosides are known as the principal pharmacological active constituents in Panax medicinal plants such as Asian ginseng, American ginseng, and Notoginseng. Some ginsenosides, especially the 20(R) isomers, are found in trace amounts in natural sources and are difficult to chemically synthesize. The present study provides an approach to produce such trace ginsenosides applying biotransformation through Escherichia coli modified with relevant genes. Methods: Seven uridine diphosphate glycosyltransferase (UGT) genes originating from Panax notoginseng, Medicago sativa, and Bacillus subtilis were synthesized or cloned and constructed into pETM6, an ePathBrick vector, which were then introduced into E. coli BL21star (DE3) separately. 20(R)-Protopanaxadiol (PPD), 20(R)-protopanaxatriol (PPT), and 20(R)-type ginsenosides were used as substrates for biotransformation with recombinant E. coli modified with those UGT genes. Results: E. coli engineered with $GT95^{syn}$ selectively transfers a glucose moiety to the C20 hydroxyl of 20(R)-PPD and 20(R)-PPT to produce 20(R)-CK and 20(R)-F1, respectively. GTK1- and GTC1-modified E. coli glycosylated the C3-OH of 20(R)-PPD to form 20(R)-Rh2. Moreover, E. coli containing $p2GT95^{syn}K1$, a recreated two-step glycosylation pathway via the ePathBrich, implemented the successive glycosylation at C20-OH and C3-OH of 20(R)-PPD and yielded 20(R)-F2 in the biotransformation broth. Conclusion: This study demonstrates that rare 20(R)-ginsenosides can be produced through E. coli engineered with UTG genes.
Keywords
biosynthesis; 20(R)-ginsenosides; ginsenoside; UDP-glycosyltransferase;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Oh M, Choi YH, Choi S, Chung H, Kim K. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 1999;14:869-75.
2 Tsutsumi YM, Tsutsumi R, Mawatari K, Nakaya Y, Kinoshita M, Tanaka K, Oshita S, Compound K. A metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/PI3K pathway. Life Sci 2011;88:725-9.   DOI
3 Shin KO, Seo CH, Cho HH. Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells. Arch Pharmacol Res 2014;37:1183-92.   DOI
4 Mai TT, Moon JY, Song YW. Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells. Cancer Lett 2012;321:144-53.   DOI
5 Siraj FM, SathishKumar N, Kim YJ. Ginsenoside F2 possesses anti-obesity activity via binding with PPAR and inhibiting adipocyte differentiation in the 3T3-L1 cell line. J Enzym Inhib Med Ch 2014;30:9-14.   DOI
6 Wei XJ, Chen J, Su F, Su XY, Hu TJ, Hu SH. Stereospecificity of ginsenoside Rg3 in promotion of the immune response to ovalbumin in mice. Int Immunol 2012;24:465-71.   DOI
7 Pi MS, Ru Q, Gong XK, Wu RH, Tian X, Xiong Q, Li CY. Effect of ginsenoside Rg2 and its stereoisomers on oxygen-glucose deprivation and reperfusion induced cortical neuronal injury model. Chin J Integr Tradit West Med 2016;36:333-8.
8 Yang XD, Yang YY, Ouyang DS, Yang GP. A review of biotransformation and pharmacology of ginsenoside compound K. Fitoterapia 2015;100:208-20.   DOI
9 Bae EA, Choo MK, Park EK, Park SY, Shin HY, Kim DH. Metabolism of ginsenoside R(c) by human intestinal bacteria and its related antiallergic activity. Biol Pharm Bull 2002;25:743-7.   DOI
10 Yan Q, Zhou XW, Zhou W, Li XW, Feng MQ, Zhou P. Purification and properties of a novel beta-glucosidase, hydrolyzing ginsenoside Rb1 to CK, from Paecilomyces bainier. J Microbiol Biotechnol 2008;18:1081-9.
11 Zhou W, Feng MQ, Li JY, Zhou P. Studies on the preparation, crystal structure and bioactivity of ginsenoside compound K. J Asian Nat Prod Res 2006;8:519-27.   DOI
12 Quan LH, Kim YJ, Li GH, Choi KT, Yang DC. Microbial transformation of ginsenoside Rb1 to compound K by Lactobacillus paralimentarius. World J Microbiol Biotechnol 2013;29:1001-7.   DOI
13 Wang RF, Zheng MM, Cao YD, Li H, Li CX, Xu JH, Wang ZT. Enzymatic transformation of vina-ginsenoside R7 to rare notoginsenoside ST-4 using a new recombinant gylcoside hydrolase from Herpetosiphon aurantiacus. Appl Microbiol Biotechnol 2015;99:3433-42.   DOI
14 Wang RF, Li J, Hu HJ, Li J, Yang YB, Yang L, Wang ZT. Chemical transformation and target preparation of saponins in stems and leaves of Panax notoginseng. J Ginseng Res 2018;42:270-6.   DOI
15 Yan X, Fan Y, Wei W, Wang PP, Liu QF, Wei YJ, Zhang L, Zhao GP, Yue JM, Zhou ZH. Production of bioactive ginsenoside compound K in metabolically engineered yeast. Cell Res 2014;24:770-3.   DOI
16 Yang WZ, Hu Y, Wu WY, Ye M, Guo DA. Saponins in the genus Panax L. (Araliaceae): a systematic review of their chemical diversity. Phytochemistry 2014;106:7-24.   DOI
17 Nicol RW, Traquair JA, Bernards MA. Ginsenosides as host resistance factors in American ginseng (Panax quinquefolius). Can J Bot 2011;80:557-62.   DOI
18 Cho WCS, Chung WS, Lee SKW, Leung AWN, Cheng CHK. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol 2006;550:173-9.   DOI
19 Wang T, Guo RX, Zhou GH, Zhou XD, Kou ZZ, Sui F, Li C, Tang LY, Wang ZJ. Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen: a review. J Ethnopharmacol 2016;188:234-58.   DOI
20 Gao B, Huang LF, Liu HS, Wu H, Zhang EY, Yang L, Wu XJ, Wang ZT. Platelet P2Y12 receptor involved in the hemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng. Br J Pharmacol 2014;171:214-23.   DOI
21 Zhao SJ, Jones JA, Lachance DM, Bhan N, Khalidi O, Venkataraman S, Wang ZT, Koffas MA. Improvement of catechin production in Escherichia coli through combinatorial metabolic engineering. Metab Eng 2015;28:43-53.   DOI
22 Liu MH, Yang BR, Cheung WF, Yang KY, Zhou HF, Kwok JS, Liu GC, Li XF, Zhong S, Lee SM, et al. Transcriptome analysis of leaves, roots and flowers of Panax notoginseng identifies genes involved in ginsenoside and alkaloid biosynthsis. BMC Genomics 2015;16:1-12.   DOI
23 Luo SL, Dang LZ, Zhang KQ, Liang LM, Li GH. Cloning and heterologous expression of UDP-glycosyltransferase genes from Bacillus subtilis and its application in the glycosylation of ginsenoside Rh1. Lett Appl Microbiol 2014;60:72-8.   DOI
24 Xu P, Vansiri A, Bhan N, Koffas MAG. ePathBrick: a synthetic biology platform for engineering metabolic pathways in E. coli. ACS Synth Biol 2012;1:256-66.   DOI
25 Liu L, Zhu XM, Wang QJ, Zhang DL, Fang ZM, Wang CY, Wang Z, Sun BS, Wu H, Sung CK. Enzymatic preparation of 20(S, R)-protopanaxadiol by transformation of 20(S,R)-Rg3 from black ginseng. Phytochemistry 2010;71:1514-20.   DOI
26 Wang PP, Wei YJ, Fan Y, Liu QF, Wei W, Yang CS, Zhang L, Zhao GP, Yue JM, Yan X, et al. Production of bioactive ginsenosides Rh2 and Rg3 by metabolically engineered yeasts. Metab Eng 2015;29:97-105.   DOI
27 Jung SC, Kim W, Park SC, Jeong J, Park MK, Lim S, Lee Y, Im WT, Lee JH, Choi G, et al. Two ginseng UDP-glycosyltransferases synthesize ginsenoside Rg3 and Rd. Plant Cell Physiol 2014;55:2177-88.   DOI
28 Shen KK, Leung SWS, Ji LL, Huang Y, Hou MQ, Xu AM, Wang ZT, Vanhoutte PM. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Biochem Pharmacol 2014;88:66-74.   DOI
29 Gao B, Shi HL, Li X, Qiu SP, Wu H, Zhang BB, Wu XJ, Wang ZT. p38 MAPK and ERK1/2 pathways are involved in the pro-apoptotic effect of notoginsenoside Ft1 on human neuroblastoma SH-SY5Y cells. Life Sci 2014;108:63-70.   DOI
30 Shen KK, Ji LL, Gong CY, Ma YB, Yang L, Fan Y, Hou MQ, Wang ZT. Notoginsenoside Ft1 promotes angiogenesis via HIF-1a mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochem Pharmacol 2012;84:784-92.   DOI
31 Zhang JJ, Ding LL, Wang BC, Ren GY, Sun AN, Deng C, Wei XH, Mani S, Wang ZT, Dou W. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. J Pharmacol Exp Ther 2015;352:1-10.
32 Deng J, Jiang YX, Ying-Li C, Chen XQ. Effects of ginsenoside CK on gastric cancer SGC-7901 cell line and endogenous VEGF secreted by tumor cells. Cancer Res Prev Treat 2011;38:17-20.